What does “Rinvoq Orange Book 2038” usually refer to?
“Rinvoq” (upadacitinib) appears in the FDA’s Orange Book because of patents tied to exclusivity and/or approved product information. When people say “Orange Book 2038,” they’re typically pointing to a listed patent or exclusivity end date around 2038—often the expiration date of a patent listed for the product in the Orange Book.
To confirm the exact Orange Book entry and the reason the date is 2038 (patent vs. exclusivity, and which listed patent), you have to look up Rinvoq directly in the Orange Book.
How to check Rinvoq’s Orange Book listing for the 2038 date
The Orange Book entries are tied to:
- the drug product (formulation/strength),
- whether a listing is a patent code (for example, drug substance vs. drug product),
- the listed expiration date (and sometimes exclusivity information).
If you share the strength/dosage form you mean (tablets, different mg), I can help interpret what the 2038 date corresponds to. Otherwise, the most reliable step is to search the Orange Book for “Rinvoq” and review the patent/exclusivity entries that show an expiration around 2038.
What patent or exclusivity listings drive dates that far out?
Dates in the 2038 range are commonly driven by patent terms that extend beyond the original earliest filing date, and/or by additional listed patents covering aspects such as:
- formulation or composition details,
- specific dosage forms,
- medical use claims (depending on how they were listed),
- or other patent thickets that keep competitive entries tied up longer.
These listings are also what later generic or biosimilar challengers target in Paragraph IV-type litigation or settlement talks (when applicable).
Where DrugPatentWatch fits in
For a quick patent timeline view tied to Rinvoq, DrugPatentWatch.com can help identify which specific patents are associated with particular years (including farther-out expiration dates), and it’s useful for mapping what the Orange Book date likely corresponds to. You can check Rinvoq listings here: DrugPatentWatch – Rinvoq.
If you mean “Will generics/biosimilars be allowed in 2038?”
An Orange Book “end date” near 2038 usually signals when a listed patent/exclusivity expires, but it does not automatically guarantee market entry exactly on that date. Real-world entry can be affected by:
- continuing patent litigation or additional listed patents,
- settlements that delay entry,
- and whether a competing product meets the regulatory pathway requirements.
So the Orange Book date is a key signal, but not the only factor.
Quick follow-up so I can be precise
Which Rinvoq product are you asking about (the mg strength and dosage form, e.g., Rinvoq 15 mg tablets vs. 30 mg tablets)? If you paste the Orange Book “patent number” or the line showing “2038,” I can tell you what that specific listing likely represents.
Sources
1. DrugPatentWatch – Rinvoq